JenaValve

Executive Summary

JenaValve is a German medical device company that has developed the Trilogy transcatheter aortic valve replacement (TAVR) system, the first FDA-approved device specifically for treating severe symptomatic aortic regurgitation (AR) in high-risk patients. Unlike traditional TAVR valves that rely on calcified anchoring, Trilogy uses unique locator technology for commissural alignment and attaches to native leaflets, enabling secure placement even in non-calcified anatomies. This addresses a critical unmet need, as AR patients previously had limited treatment options beyond high-risk surgery. The company is private and based in Munich, Germany. The FDA approval positions JenaValve to capture a niche but growing segment of the TAVR market. Clinical data support favorable outcomes, and the device's differentiated design offers a competitive edge. With an aging population and increasing awareness of AR, adoption is expected to accelerate. Near-term focus will be on commercial rollout, reimbursement expansion, and generating real-world evidence. JenaValve represents a compelling opportunity in structural heart innovation, though it faces competition from larger players developing AR-specific valves.

Upcoming Catalysts (preview)

• Q3 2026Commercial launch and first revenue milestone80% success
• Q4 2026Presentation of 1-year post-market clinical data at major cardiology conference70% success